Breaking news

23andMe Files For Chapter 11: Anne Wojcicki Resigns Amid Struggles to Revive Company

by THEFUTURE.TEAM

March 26, 2025

In a bold and unexpected move, 23andMe has filed for Chapter 11 bankruptcy, signaling the company’s struggle to stay afloat amid mounting financial pressure. In its filing with the Eastern District of Missouri federal bankruptcy court, the DNA testing giant revealed it has initiated the process of selling its assets in an attempt to salvage what’s left of its business. Despite the looming uncertainty, 23andMe reassured customers that it would continue operations throughout the asset sale process, emphasizing that there would be no disruptions to how customer data is stored, managed, or protected.

If the bankruptcy court approves its Chapter 11 plan, 23andMe will embark on a 45-day window to solicit bids. If multiple buyers emerge, the company will hold an auction to maximize its value. A key condition for any potential buyer: they must adhere to legal requirements for handling customer data, a significant concern after recent breaches.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

In a related shakeup, co-founder Anne Wojcicki, who once helmed the company, has stepped down as CEO. However, Wojcicki isn’t entirely distancing herself from the company—she will remain on 23andMe’s board and is reportedly preparing to bid on the company’s assets herself. Her resignation follows a failed attempt to take 23andMe private. Last month, she made a bid to acquire the company for $2.53 per share, but the deal collapsed when her partner, New Mountain Capital, pulled out. This was followed by a new bid this month, offering just 41 cents per share—a move swiftly rejected by the company’s board. In a statement on X (formerly Twitter), Wojcicki expressed her disappointment, but also her intent to pursue the company’s assets independently, citing her resignation as a strategic move to position herself better for the bidding process.

The Rise And Fall Of 23andMe

Once a market darling, 23andMe went public in 2021 through a merger with a Special Purpose Acquisition Company (SPAC), reaching a market cap of $6 billion. Wojcicki, a co-founder of the company, saw her fortune soar into the billions. But since then, the company’s stock has plummeted by over 99%, as it failed to reach profitability despite its promising start.

Adding fuel to the fire, the company suffered a major data breach in 2023, when hackers exploited recycled passwords to access sensitive user data. The breach involved over a million genetic data points, including information from high-profile individuals, and was shared across hacker forums. The exposed data included genetic ancestry, birth years, and even personal details of well-known tech figures such as Mark Zuckerberg and Elon Musk. In the aftermath, 23andMe settled in court, agreeing to pay $30 million and offer three years of security monitoring to those affected by the breach.

As 23andMe enters its next phase under bankruptcy proceedings, the company faces a steep uphill battle to regain trust and value. The fate of its assets—and its brand—now rests in the hands of potential buyers.

The Future Forbes Realty Global Properties

China’s Dominance In Humanoid Robotics: Accelerating Innovation And Strategic Growth

China’s rapid progress in humanoid robotics is reshaping the global industrial landscape, propelled by aggressive innovation and strong government support. From high-profile demonstrations at the Spring Festival Gala to upcoming showcases such as Honor’s debut at Mobile World Congress, Chinese companies are increasingly positioning themselves at the center of the global race for humanoid robotics leadership.

From Festive Demos To Operational Integration

Recent showcases signal a shift from promotional demonstrations toward practical deployment. According to Selina Xu, China and AI Policy lead at the office of Eric Schmidt, China’s mature hardware supply chain and large-scale manufacturing ecosystem allow companies to iterate faster and move prototypes into production more efficiently. This speed-to-market advantage has enabled firms such as Unitree to ship significantly more units than U.S. competitors, including Figure and Tesla, highlighting the country’s growing industrial leverage.

Investment And The Drive For Scale

Capital inflows are accelerating commercialization. Unitree’s valuation reached roughly $3 billion following its Series C round, while reports suggest the company is targeting a potential $7 billion IPO. Galbot has also attracted substantial investor interest, raising more than $300 million in a recent funding round. The scale of investment reflects confidence that humanoid robotics is moving beyond experimentation toward viable industrial and commercial applications.

Addressing Core Technological And Regulatory Challenges

Despite rapid hardware progress, major technical barriers remain. Developers continue to face challenges in building AI systems capable of reliably predicting physical interactions in complex environments. Nvidia currently leads with its end-to-end humanoid software ecosystem, while Chinese chipmakers are working to establish domestic alternatives. Safety standards, data availability, and the need for large-scale simulation environments remain key constraints as companies seek to achieve dependable autonomy.

A Global Race With Diverse Regional Strengths

China’s combination of policy support and manufacturing capacity gives it a strong competitive advantage, but other regions remain active. Japan and South Korea continue to leverage decades of robotics expertise, with companies such as Honda, Murata Manufacturing, and SoftBank Robotics focusing on applications including eldercare and service automation. In the United States, firms like Foundation are prioritizing real-world deployment and targeting production volumes in the tens of thousands by 2027. This global contest highlights a complex interplay of innovation, strategic policy, and industrial momentum that will define the future of humanoid robotics.